Analysis finds no lawful compounding path for Lilly's retatrutide

A legal analysis published August 18, 2026 concludes that retatrutide, the experimental obesity drug Eli Lilly is still testing, has no lawful compounding pathway. The assessment from the law firm Frier Levitt follows the six federal lawsuits Lilly filed on August 12, 2026 against businesses accused of selling the unapproved substance ^[1].

The analysis walks through three requirements of Section 503A of the federal Food, Drug, and Cosmetic Act and finds retatrutide meets none of them. It is not a component of an FDA-approved drug. It does not appear on the FDA's list of bulk drug substances that pharmacies may compound with. And no United States Pharmacopeia or National Formulary monograph covers it ^[1]. The FDA has said retatrutide "cannot be used in compounding under federal law," the firm notes ^[1].

Retatrutide has not been approved by the FDA or by any regulator worldwide ^[1]. It acts on three hormone receptors — GLP-1, GIP and glucagon — and in trials Lilly has gathered evidence of greater weight loss than with Zepbound and Mounjaro, its marketed drugs containing tirzepatide ^[1]. The drug is still in Phase 3 testing, and Lilly does not expect to file for FDA approval until 2027 ^[1]. Until then, the analysis states, the only routes to retatrutide are Lilly-sponsored clinical trials or, in limited situations, the FDA's expanded access program ^[1].

What the lawsuits cover

The six complaints, filed in four federal district courts in Texas, name four "research-use-only" sellers, one medical spa and one compounding pharmacy ^[1]. Lilly is asking for a permanent injunction that would bar each defendant from manufacturing, marketing, distributing, dispensing or selling anything containing or purporting to contain retatrutide, along with disgorgement of profits and attorney's fees ^[1]. According to the analysis, the research-use-only sellers attached that label, meant for laboratory work, to products Lilly alleges were marketed for human use ^[1]. The medical spa is accused of advertising a "Triple G" retatrutide product on its website and social media. The pharmacy is accused of selling retatrutide to medical spas and providers ^[1]. Lilly's public description of such businesses: they "are not practicing medicine; they are selling illegal drugs" ^[1].

Most of the claims rest on state unfair competition and consumer protection laws in Texas, Tennessee, Washington, North Carolina, South Carolina, Colorado, Connecticut and Alaska, with a single federal Lanham Act false-advertising claim against the medical spa ^[1]. The analysis reads the approach as a lower-friction route than patent litigation, which would put Lilly's patent portfolio in play at an early stage ^[1]. Separately, Lilly reports it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and licensing boards, and has flagged more than 14,000 websites, advertisements and social media listings offering retatrutide worldwide ^[1].

The retatrutide cases sit inside a longer campaign. Lilly has brought dozens of federal suits and at least five challenges before the National Advertising Division, a self-regulatory advertising body, while Novo Nordisk has filed 130 federal lawsuits and five NAD challenges. The FDA has issued more than 100 warning letters over misbranded compounded GLP-1 claims in the past year ^[2].

Why it matters for patients

Anything sold today as retatrutide sits outside FDA approval, and the analysis says there is no lawful retail, pharmacy or wellness channel for it ^[1]. Because such products are unregulated, Lilly argues they may be counterfeit, impure or dosed incorrectly ^[1].

The contrast with compounded semaglutide and tirzepatide is central. Those are approved drugs, and pharmacies were permitted to compound copies under shortage-based exceptions while supply shortages remained in effect ^[1]. Retatrutide has never been approved, so no comparable exception applies. A pharmacy that compounds it now faces civil suits from the manufacturer in addition to possible FDA warning letters, according to the analysis ^[1].

One question is unresolved: how retatrutide would be regulated if it is approved. Lilly has contested the FDA's determination of its status, and a federal court vacated and remanded part of the agency's decision on whether the drug is "analogous" to a protein. If retatrutide ends up regulated as a biological product under Section 351 of the Public Health Service Act, the drug-compounding exemptions in the FDCA would not open a path to copies ^[1]. How that dispute will be settled has not been reported.

What happens next

Lilly expects to submit an FDA application for retatrutide in 2027. No narrower timeframe has been disclosed ^[1]. No rulings in the six August lawsuits have been reported ^[1]. In a separate matter, Strive Compounding Pharmacy filed a federal antitrust suit in the Western District of Texas in January 2026 against Lilly and Novo Nordisk, alleging the manufacturers used exclusive agreements with telehealth platforms to block those platforms from working with compounding pharmacies ^[2].